156 related articles for article (PubMed ID: 10853668)
1. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.
Buckman BO; Mohan R; Koovakkat S; Liang A; Trinh L; Morrissey MM
Bioorg Med Chem Lett; 1998 Aug; 8(16):2235-40. PubMed ID: 9873520
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
Phillips GB; Buckman BO; Davey DD; Eagen KA; Guilford WJ; Hinchman J; Ho E; Koovakkat S; Liang A; Light DR; Mohan R; Ng HP; Post JM; Shaw KJ; Smith D; Subramanyam B; Sullivan ME; Trinh L; Vergona R; Walters J; White K; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 1998 Sep; 41(19):3557-62. PubMed ID: 9733480
[No Abstract] [Full Text] [Related]
6. Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031).
Light DR; Guilford WJ
Curr Top Med Chem; 2001 Jun; 1(2):121-36. PubMed ID: 11899248
[TBL] [Abstract][Full Text] [Related]
7. Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1494-504. PubMed ID: 17917295
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor.
Nishida H; Miyazaki Y; Kitamura Y; Ohashi M; Matsusue T; Okamoto A; Hosaka Y; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1237-44. PubMed ID: 11605647
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
Hirayama F; Koshio H; Katayama N; Ishihara T; Kaizawa H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kurihara H; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2003 Feb; 11(3):367-81. PubMed ID: 12517432
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
Han Q; Dominguez C; Stouten PF; Park JM; Duffy DE; Galemmo RA; Rossi KA; Alexander RS; Smallwood AM; Wong PC; Wright MM; Luettgen JM; Knabb RM; Wexler RR
J Med Chem; 2000 Nov; 43(23):4398-415. PubMed ID: 11087565
[TBL] [Abstract][Full Text] [Related]
12. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.
Matter H; Defossa E; Heinelt U; Blohm PM; Schneider D; Müller A; Herok S; Schreuder H; Liesum A; Brachvogel V; Lönze P; Walser A; Al-Obeidi F; Wildgoose P
J Med Chem; 2002 Jun; 45(13):2749-69. PubMed ID: 12061878
[TBL] [Abstract][Full Text] [Related]
13. Indoline derivatives I: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Matsui Y; Fujimoto K
Chem Pharm Bull (Tokyo); 2006 Feb; 54(2):163-74. PubMed ID: 16462058
[TBL] [Abstract][Full Text] [Related]
14. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.
Chou YL; Davey DD; Eagen KA; Griedel BD; Karanjawala R; Phillips GB; Sacchi KL; Shaw KJ; Wu SC; Lentz D; Liang AM; Trinh L; Morrissey MM; Kochanny MJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):507-11. PubMed ID: 12565961
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups.
Phillips G; Guilford WJ; Buckman BO; Davey DD; Eagen KA; Koovakkat S; Liang A; McCarrick M; Mohan R; Ng HP; Pinkerton M; Subramanyam B; Ho E; Trinh L; Whitlow M; Wu S; Xu W; Morrissey MM
J Med Chem; 2002 Jun; 45(12):2484-93. PubMed ID: 12036356
[TBL] [Abstract][Full Text] [Related]
17. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
Dudley DA; Bunker AM; Chi L; Cody WL; Holland DR; Ignasiak DP; Janiczek-Dolphin N; McClanahan TB; Mertz TE; Narasimhan LS; Rapundalo ST; Trautschold JA; Van Huis CA; Edmunds JJ
J Med Chem; 2000 Nov; 43(22):4063-70. PubMed ID: 11063603
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one skeleton.
Nishida H; Mukaihira T; Saitoh F; Harada K; Fukui M; Matsusue T; Okamoto A; Hosaka Y; Matsumoto M; Shiromizu I; Ohnishi S; Mochizuki H
Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):406-12. PubMed ID: 15056953
[TBL] [Abstract][Full Text] [Related]
19. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.
Huang W; Zhang P; Zuckett JF; Wang L; Woolfrey J; Song Y; Jia ZJ; Clizbe LA; Su T; Tran K; Huang B; Wong P; Sinha U; Park G; Reed A; Malinowski J; Hollenbach SJ; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2003 Feb; 13(3):561-6. PubMed ID: 12565972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
